ICS 2016 Scientific Podium Short Oral Session S26 - Botulinum Toxin and the Lower Urinary Tract

Speakers
	Friday 16th September 2016
	11:00 - 12:30
	Hall D5 Capacity: 200
D Dudley Timothy Robinson ICS Chair T Tomonori Yamanishi ICS Chair B Brigitte Schürch ICS Chair

11:00

#459 Bacteriuria in patients undergoing intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity: Do we need antibiotic prophylaxis?

Presenter: Lorenz Leitner

Leitner L¹, Sammer U², Walter M², Knüpfer S C², Schneider M P², Seifert B³, Mehnert U², Kessler T M²
1. Neuro-Urology, Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital and Department of Urology, University Hospital Basel, 2. Neuro-Urology, Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital, 3. Epidemiology, Biostatistics and Prevention Institute, Department of Biostatistics, University of Zürich
Clinical Trial, Prospective Study, Infection, Urinary Tract

11:07

#460 Different types and dosages of intradetrusor Botulinum Toxin A injections in spinal cord patients: a single centre experience in 15-years follow-up.

Presenter: Stefania Musco

Musco S¹, Del Popolo G¹, Celso M¹, Bellio E¹, Bellio V¹, Lombardi G¹
1. Neuro-Urology Dept, University Hospital Careggi, Florence, Italy
Incontinence, Detrusor Overactivity, Retrospective Study, Spinal Cord Injury

11:15

#461 Comparison of intradetrusor injections of botulinum toxin A in adult patients with spina bifida and in patients with spinal cord injury : a multicenter study

Presenter: Benoit Peyronnet

Peyronnet B¹, Hascoet J¹, Castel-Lacanal E², Roumiguie M², Senal N¹, Kerdraon J¹, Marque P², Manunta A¹, Gamé X²
1. Rennes University Hospital, 2. Toulouse University Hospital
Spinal Cord Injury, Conservative Treatment, Detrusor Overactivity, Neuropathies: Central

11:22

#462 Intradetrusor injections of botulinum toxin A in patients with spinal dysraphism: results of a multicenter study

Presenter: Benoit Peyronnet

Peyronnet B¹, Even Schneider A², Verrando A³, De Sèze M⁴, Hascoet J¹, Castel-Lacanal E⁵, Chartier-Kastler E⁶, Schurch B⁷, Denys P², Manunta A¹, Amarenco G³, Gamé X⁵
1. Rennes University Hospital, 2. Raymond Poincaré Hospital, 3. Tenon Hospital, 4. Saint-Augustin institute, 5. Toulouse University Hospital, 6. Pitié-Salpétrière Hospital, 7. Lausanne University Hospital
Neuropathies: Central, Detrusor Overactivity, Conservative Treatment

11:30

#463 Deficits of urothelial E-cadherin and zonula occludens-1 in chronic spinal cord injured bladders improved after repeated detrusor onabotulinumtoxinA injections

Presenter: Sheng-Fu Chen

Chen S¹, Lee Y¹, Lee C¹, Chang J¹, Kuo H¹
1. Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan
Physiology, Basic Science, Neuropathies: Peripheral

11:37

#464 Long term real life efficacy of onabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in a population using intermittent self-catheterization.

Presenter: Charles Joussain

Joussain C¹, Popoff M², Phé V³, Even Schneider A², Falcou L², Chartier-Kastler E⁴, Schurch B⁵, Denys P⁶
1. Medical School Paris Île-de-France Ouest, Inserm U1179, Versailles Saint-Quentin University, Versailles, France. - Paris Saclay, 2. Department of Physical Medicine and Rehabilitation, Hôpital Raymond-Poincaré AP-HP, Garches, France, 3. Pitié-Salpêtrière Academic Hospital, Department of Urology, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, Paris 6 University, Paris, France, 4. Pitié-Salpêtrière Academic Hospital, Department of Urology, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, Paris 6 University, Paris, France., 5. Neuropsychology and Neurorehabilitation Service, Department of Clinical Neuroscience, Lausanne University Hospital, Lausanne, Switzerland, 6. Medical School Paris Île-de-France Ouest, Inserm U1179, Versailles Saint-Quentin University, Versailles, France. Department of Physical Medicine and Rehabilitation, Hôpital Raymond-Poincaré AP-HP, Garches, France
Overactive Bladder, Detrusor Overactivity, Incontinence, Spinal Cord Injury, Multiple Sclerosis

11:45

#465 Long-term follow-up of patients who failed intravesical botulinum toxin A injections

Presenter: Tom Marcelissen

Marcelissen T¹, Rahnama'i S², Brierly B³, de Vries P²
1. Maastricht University Medical Centre, 2. Zuyderland Medical Centre, Heerlen, 3. Maastricht University
Female, Incontinence, Overactive Bladder

11:52

#466 Botulinum toxin urethral sphincter injection as treatment for non-neurogenic voiding dysfunction – A randomized, double-Blind, placebo-controlled study

Presenter: Yuan-Hong Jiang

Jiang Y¹, Wu S¹, Lee C¹, Kuo H¹
1. Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan
Clinical Trial, Pathophysiology, Voiding Dysfunction

12:00

#467 Redefining the indication to repeat onabotulinum toxin A in patients with neurogenic detrusor overactivity (NDO) after spinal cord injury (SCI).

Presenter: Dinesh Suman

Suman D¹
1. Isic ,New Delhi
Incontinence, Spinal Cord Injury, Detrusor Overactivity, Retrospective Study

12:07

#468 Assessment of pain during administration of botulinum toxin bladder injections with and without the use of intravesical lidocaine instillation

Presenter: Seong Shin

Shin S¹, Hadjipavlou M², Sharma D², Sabbagh S²
1. St George's University of London, 2. St George's University Hospitals NHS Foundation Trust
Detrusor Overactivity, Overactive Bladder, Pain, other, Questionnaire, Retrospective Study

12:15

#469 Efficacy and safety of botulinum toxin A treatment for patients with detrusor overactivity and inadequate contractility

Presenter: Chung-Cheng Wang

Wang C¹, Jiang Y², Ong H², Tian J², Kuo H²
1. Department of Urology, En Chu Kong Hospital, New Taipei City, Taiwan, 2. Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan
Pharmacology, Incontinence, Underactive Bladder

12:22

#470 DOES INTRAPROSTATIC INJECTION OF BOTULINUM TOXIN-A REDUCE POST-VOID RESIDUAL IN BENIGN PROSTATIC HYPERPLASIA?

Presenter: Elena Andretta

Andretta E¹, Viaggi S², Pastorello M³, Seren P⁴, Artuso G⁵
1. Urology Department - General Hospital DOLO (Venice) ITALY, 2. MediNeos Observational Research – MODENA, 3. Urology Department - General Hospital NEGRAR (Verona), 4. Urology Department - General Hospital DOLO (Venice), 5. Urology Department - General Hosptal DOLO (Venice)
Benign Prostatic Hyperplasia (BPH), Prospective Study, Conservative Treatment

Content Visitors (staff only)

Botulinum Toxin and the Lower Urinary Tract

Scientific Podium Short Oral Session S26

Session Schedule

Comments

Chat